Long-term safety and efficacy of DTX301 in adults with late-onset ornithine transcarbamylase (OTC) deficiency: A Phase 1/2 trial

被引：1
|
作者：
Thomas, Janet [1 ,2 ]
Tan, Wen-Hann [3 ]
Khan, Aneal [4 ,5 ]
Konczal, Laura [6 ]
Breilyn, Margo Sheck [7 ]
Hualde, Leticia Ceberio [8 ]
Couce, Marie Luz [9 ]
Geberhiwot, Tarekegn [10 ]
Guffon, Nathalie [11 ]
Harding, Cary [12 ]
Patra, Kaushik [13 ]
Merritt, J. Lawrence, II [13 ]
Crombez, Eric [13 ]
机构：
[1] Univ CO, Sch Med, Aurora, CO USA
[2] Childrens Hosp Colorado, Aurora, CO USA
[3] Harvard Med Sch, Boston Childrens Hosp, Boston, MA 02115 USA
[4] MAGIC Clin Ltd, Calgary, AB, Canada
[5] Univ Calgary, Calgary, AB, Canada
[6] Univ Hosp Cleveland Med Ctr, Cleveland, OH USA
[7] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[8] Cruces Univ Hosp, Biocruces Bizkaia Hlth Res Inst, Baracaldo, Spain
[9] Univ Santiago De Compostela, Santiago De Compostela, Spain
[10] Univ Birmingham, Birmingham, W Midlands, England
[11] HCL, Reference Ctr Inherited Metab Dis, Lyon, France
[12] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[13] Ultragenyx Pharmaceut Inc, Novato, CA USA
来源：
MOLECULAR GENETICS AND METABOLISM | 2024年 / 141卷 / 04期
关键词：
D O I：
10.1016/j.ymgme.2024.108266
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Poster # 0
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALKþ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
    Gettinger, Scott N.
    Huber, Rudolf M.
    Kim, Dong-Wan
    Bazhenova, Lyudmila
    Hansen, Karin Holmskov
    Tiseo, Marcello
    Langer, Corey J.
    Rodriguez, Luis G. Paz-Ares
    West, Howard L.
    Reckamp, Karen L.
    Weiss, Glen J.
    Smit, Egbert F.
    Hochmair, Maximilian J.
    Kim, Sang-We
    Ahn, Myung-Ju
    Kim, Edward S.
    Groen, Harry J. M.
    Pye, Joanna
    Liu, Yuyin
    Zhang, Pingkuan
    Vranceanu, Florin
    Camidge, Ross
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (09):
  • [42] Long-Term Safety and Efficacy of Mitapivat, an Oral Pyruvate Kinase Activator, in Adults with Sickle Cell Disease: Extension of a Phase 1 Dose Escalation Study
    Conrey, Anna
    Frey, Ingrid
    Asomaning, Nancy
    Charles, Ruth Pierre
    Parekh, Dina
    Xu, Julia
    Le, Kang
    Kruah, Britney
    Li, Quan
    Dunkelberger, Emily
    Cellmer, Troy
    Yates, Amber M.
    Wind-Rotolo, Megan
    Jeffries, Neal
    Eaton, William A.
    Thein, Swee Lay
    BLOOD, 2023, 142
  • [43] Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)
    McElvaney, Noel G.
    Burdon, Jonathan
    Holmes, Mark
    Glanville, Allan
    Wark, Peter A. B.
    Thompson, Philip J.
    Hernandez, Paul
    Chlumsky, Jan
    Teschler, Helmut
    Ficker, Joachim H.
    Seersholm, Niels
    Altraja, Alan
    Makitaro, Riitta
    Chorostowska-Wynimko, Joanna
    Sanak, Marek
    Stoicescu, Paul I.
    Piitulainen, Eeva
    Vit, Oliver
    Wencker, Marion
    Tortorici, Michael A.
    Fries, Michael
    Edelman, Jonathan M.
    Chapman, Kenneth R.
    LANCET RESPIRATORY MEDICINE, 2017, 5 (01): : 51 - 60
  • [44] Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
    Busse, William W.
    Bleecker, Eugene R.
    FitzGerald, J. Mark
    Ferguson, Gary T.
    Barker, Peter
    Sproule, Stephanie
    Olsson, Richard F.
    Martin, Ubaldo J.
    Goldman, Mitchell
    LANCET RESPIRATORY MEDICINE, 2019, 7 (01): : 46 - 59
  • [45] Long-term efficacy and safety of eslicarbazepine acetate: Results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy
    Halasz, Peter
    Cramer, Joyce A.
    Hodoba, Danilo
    Czlonkowska, Anna
    Guekht, Alla
    Maia, Joana
    Elger, Christian
    Almeida, Luis
    Soares-da-Silva, Patricio
    EPILEPSIA, 2010, 51 (10) : 1963 - 1969
  • [46] Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: Results from a phase III open-label extension trial
    Husain, Aatif
    Chung, Steve
    Faught, Edward
    Isojarvi, Jouko
    McShea, Cindy
    Doty, Pamela
    EPILEPSIA, 2012, 53 (03) : 521 - 528
  • [47] Long-term efficacy and safety of enavogliflozin in Korean people with type 2 diabetes: A 52-week extension of a Phase 3 randomized controlled trial
    Kwak, Soo Heon
    Han, Kyung Ah
    Kim, Eun Sook
    Choi, Sung Hee
    Won, Jong Chul
    Yu, Jae Myung
    Oh, Seungjoon
    Yoo, Hye Jin
    Kim, Chong Hwa
    Kim, Kyung-Soo
    Chun, Sungwan
    Kim, Yong Hyun
    Cho, Seung Ah
    Kim, Da Hye
    Park, Kyong Soo
    DIABETES OBESITY & METABOLISM, 2024, 26 (10): : 4203 - 4212
  • [48] Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2
    Karppa, Mikko
    Yardley, Jane
    Pinner, Kate
    Filippov, Gleb
    Zammit, Gary
    Moline, Margaret
    Perdomo, Carlos
    Inoue, Yuichi
    Ishikawa, Kohei
    Kubota, Naoki
    SLEEP, 2020, 43 (09) : 1 - 11
  • [49] LONG-TERM EFFICACY AND SAFETY OF PONATINIB IN HEAVILY PRETREATED LEUKEMIA PATIENTS: 4-YEAR RESULTS FROM THE PIVOTAL PHASE 2 PACE TRIAL
    Cortes, J. E.
    Pinilla-Ibarz, J.
    le Coutre, P. D.
    Paquette, R.
    Chuah, C.
    Nicolini, F. E.
    Apperley, J. F.
    Khoury, H. J.
    Talpaz, M.
    Baccarani, M.
    Lustgarten, S.
    Haluska, F. G.
    Guilhot, F.
    Deininger, M. W.
    Hochhaus, A.
    Hughes, T. P.
    Shah, N. P.
    Kantarjian, H. M.
    HAEMATOLOGICA, 2016, 101 : 60 - 61
  • [50] LONG- TERM SAFETY AND EFFICACY OF FAZIRSIRAN IN PATIENTS WITH ALPHA-1 ANTITRYPSIN DEFICIENCY-ASSOCIATED LIVER DISEASE ENROLLED IN THE PHASE 2 PLACEBO- CONTROLLED SEQUOIA TRIAL
    Clark, Virginia
    Strange, Charlie
    Strnad, Pavel
    Hamilton, James
    Zhou, Rong
    Schluep, Thomas
    Wyman, Anne
    Gonzalez, Susana
    Zhang, Yanwei
    Loomba, Rohit
    HEPATOLOGY, 2024, 80 : S1907 - S1908
12345